This Cordcyte market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to regulatory approvals, the rising prevalence of cancer, increasing healthcare spending, the expansion of global healthcare infrastructure, and the growing demand for immunotherapies.
The projected growth in the forecast period is driven by the increasing elderly population, favorable reimbursement policies, the expansion of clinical trial data, growing awareness of rare cancers, and changes in the regulatory landscape. Key trends in this period include personalized medicine, technological progress in cord blood banking, a rise in clinical trials involving stem cells, the emergence of new markets for cord blood banking, and the expansion of cord blood banking services.
The growing prevalence of chronic diseases is expected to drive the expansion of the cordcyte market. Chronic diseases are long-term conditions that require continuous treatment and management. Factors such as an aging population, unhealthy lifestyle choices, and environmental influences are contributing to the rise in chronic diseases. Cordcyte, which uses stem cells from umbilical cord blood for regenerative therapy, is used to treat various conditions including hematological disorders, immune deficiencies, and neurodegenerative diseases. For example, a report from the American College of Cardiology in August 2022 predicted significant increases in cardiovascular risk factors in the U.S. by 2060, with the most notable rise in diabetes (from 39.3% to 55 million), followed by dyslipidemia, hypertension, and obesity. The report also forecasted an increase in cardiovascular diseases, including strokes, heart failure, ischemic heart disease, and heart attacks. As chronic diseases become more prevalent, the demand for cordcyte treatments is expected to grow.
The increase in clinical trials is anticipated to further boost the growth of the cordcyte market. This rise is fueled by a growing demand for innovative treatments, advancements in stem cell technologies, and regulatory support for new therapies. Clinical trials play a key role in demonstrating the safety and effectiveness of cordcyte, which leads to regulatory approvals and wider adoption in treatments. For example, the American Society of Gene & Cell Therapy reported a 10% increase in the number of gene therapies in Phase III clinical trials in Q3 2023, marking the first rise since Q3 2022. This uptick in clinical trials is expected to drive the growth of the cordcyte market.
The growth of healthcare expenditure is expected to significantly contribute to the expansion of the cordcyte market. Healthcare expenditure refers to the total spending on health services and products during a given period. This increase is driven by factors such as an aging population, rising healthcare costs, and advances in medical technology. Higher healthcare spending plays a crucial role in advancing cordcyte applications by funding research, clinical trials, and infrastructure, which, in turn, supports broader access to regenerative therapies for complex diseases. For instance, in December 2023, the Centers for Medicare & Medicaid Services reported a 4.1% increase in U.S. healthcare spending in 2022, reaching $4.5 trillion, which was a faster rise compared to 2021. As healthcare expenditure continues to rise, it is expected to drive the growth of the cordcyte market.
The key company operating in the cordcyte market is LifeSouth Community Blood Centers Inc.
North America was the largest region in the cordcyte market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cordcyte report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cordcyte market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cordcyte is a therapeutic product derived from human cord blood, specifically from hematopoietic progenitor cells. It is primarily used in allogeneic hematopoietic stem cell transplants to treat patients with hematopoietic system disorders, including inherited conditions and those resulting from treatments such as chemotherapy. These cells are administered to patients to help regenerate blood and immune systems.
The primary forms of cordcyte are cord blood stem cells and cryopreserved units. Cord blood stem cells, which are potent cells found in the umbilical cord blood, have the ability to differentiate into various types of cells. These cells are utilized in therapies to address conditions such as cancers, blood diseases, and immune disorders. They are preferred for transplantation because they have a lower risk of rejection. Cordcyte is used to treat a range of conditions, including hematological disorders, genetic disorders, and immune system disorders, and is distributed through various channels, including hospital pharmacies, stem cell banks, and outpatient clinics.
The cordcyte market research report is one of a series of new reports that provides cordcyte market statistics, including the cordcyte industry's global market size, regional shares, competitors with a cordcyte market share, detailed cordcyte market segments, market trends and opportunities, and any further data you may need to thrive in the cordcyte industry. This cordcyte market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cordcyte market consists of sales of exosome-based products, stem cell transplants, and cell storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to regulatory approvals, the rising prevalence of cancer, increasing healthcare spending, the expansion of global healthcare infrastructure, and the growing demand for immunotherapies.
The projected growth in the forecast period is driven by the increasing elderly population, favorable reimbursement policies, the expansion of clinical trial data, growing awareness of rare cancers, and changes in the regulatory landscape. Key trends in this period include personalized medicine, technological progress in cord blood banking, a rise in clinical trials involving stem cells, the emergence of new markets for cord blood banking, and the expansion of cord blood banking services.
The growing prevalence of chronic diseases is expected to drive the expansion of the cordcyte market. Chronic diseases are long-term conditions that require continuous treatment and management. Factors such as an aging population, unhealthy lifestyle choices, and environmental influences are contributing to the rise in chronic diseases. Cordcyte, which uses stem cells from umbilical cord blood for regenerative therapy, is used to treat various conditions including hematological disorders, immune deficiencies, and neurodegenerative diseases. For example, a report from the American College of Cardiology in August 2022 predicted significant increases in cardiovascular risk factors in the U.S. by 2060, with the most notable rise in diabetes (from 39.3% to 55 million), followed by dyslipidemia, hypertension, and obesity. The report also forecasted an increase in cardiovascular diseases, including strokes, heart failure, ischemic heart disease, and heart attacks. As chronic diseases become more prevalent, the demand for cordcyte treatments is expected to grow.
The increase in clinical trials is anticipated to further boost the growth of the cordcyte market. This rise is fueled by a growing demand for innovative treatments, advancements in stem cell technologies, and regulatory support for new therapies. Clinical trials play a key role in demonstrating the safety and effectiveness of cordcyte, which leads to regulatory approvals and wider adoption in treatments. For example, the American Society of Gene & Cell Therapy reported a 10% increase in the number of gene therapies in Phase III clinical trials in Q3 2023, marking the first rise since Q3 2022. This uptick in clinical trials is expected to drive the growth of the cordcyte market.
The growth of healthcare expenditure is expected to significantly contribute to the expansion of the cordcyte market. Healthcare expenditure refers to the total spending on health services and products during a given period. This increase is driven by factors such as an aging population, rising healthcare costs, and advances in medical technology. Higher healthcare spending plays a crucial role in advancing cordcyte applications by funding research, clinical trials, and infrastructure, which, in turn, supports broader access to regenerative therapies for complex diseases. For instance, in December 2023, the Centers for Medicare & Medicaid Services reported a 4.1% increase in U.S. healthcare spending in 2022, reaching $4.5 trillion, which was a faster rise compared to 2021. As healthcare expenditure continues to rise, it is expected to drive the growth of the cordcyte market.
The key company operating in the cordcyte market is LifeSouth Community Blood Centers Inc.
North America was the largest region in the cordcyte market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cordcyte report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cordcyte market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cordcyte is a therapeutic product derived from human cord blood, specifically from hematopoietic progenitor cells. It is primarily used in allogeneic hematopoietic stem cell transplants to treat patients with hematopoietic system disorders, including inherited conditions and those resulting from treatments such as chemotherapy. These cells are administered to patients to help regenerate blood and immune systems.
The primary forms of cordcyte are cord blood stem cells and cryopreserved units. Cord blood stem cells, which are potent cells found in the umbilical cord blood, have the ability to differentiate into various types of cells. These cells are utilized in therapies to address conditions such as cancers, blood diseases, and immune disorders. They are preferred for transplantation because they have a lower risk of rejection. Cordcyte is used to treat a range of conditions, including hematological disorders, genetic disorders, and immune system disorders, and is distributed through various channels, including hospital pharmacies, stem cell banks, and outpatient clinics.
The cordcyte market research report is one of a series of new reports that provides cordcyte market statistics, including the cordcyte industry's global market size, regional shares, competitors with a cordcyte market share, detailed cordcyte market segments, market trends and opportunities, and any further data you may need to thrive in the cordcyte industry. This cordcyte market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cordcyte market consists of sales of exosome-based products, stem cell transplants, and cell storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cordcyte Market Characteristics4. Cordcyte Market Trends and Strategies5. Cordcyte Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Cordcyte Pricing Analysis & Forecasts30. Global Cordcyte Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Cordcyte Market32. Recent Developments in the Cordcyte Market
3. Cordcyte Market Biologic Drug Characteristics
6. Global Cordcyte Growth Analysis and Strategic Analysis Framework
8. Cordcyte Market Segmentation
9. Global Cordcyte Epidemiology of Clinical Indications
10. Cordcyte Market Regional and Country Analysis
11. Asia-Pacific Cordcyte Market
12. China Cordcyte Market
13. India Cordcyte Market
14. Japan Cordcyte Market
15. Australia Cordcyte Market
16. South Korea Cordcyte Market
17. Western Europe Cordcyte Market
18. UK Cordcyte Market
19. Germany Cordcyte Market
20. France Cordcyte Market
21. Eastern Europe Cordcyte Market
22. North America Cordcyte Market
23. USA Cordcyte Market
24. Canada Cordcyte Market
25. South America Cordcyte Market
26. Middle East Cordcyte Market
27. Africa Cordcyte Market
28. Cordcyte Market Competitive Landscape and Company Profiles
29. Global Cordcyte Market Pipeline Analysis
33. Cordcyte Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Cordcyte Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cordcyte market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cordcyte? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cordcyte market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Cord Blood Stem Cells; Cryopreserved Units2) by Indication: Hematological Disorders; Genetic Disorders; Immune System Disorders
3) by Distribution Channel: Hospital Pharmacies; Stem Cell Banks; Outpatient Clinics
Key Companies Mentioned: LifeSouth Community Blood Centers Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- LifeSouth Community Blood Centers Inc.
